Editor’s Note, DCMS #121

Jan 27, 2013
1,689 views

Hypertension can be an expensive disease and how poor a job we do managing it in older patients can increase managed care costs. This week’s Homerun Slides series, Hypertension in the Medicare Population, Part 1 of 2, provides you with the information to talk to your colleagues about the future of care for these people, and how much it is going to cost us.

Our Clinical Text has case studies on hypoglycemia caused by insulin secretagogues and you can use them to test your knowledge of this area of diabetic emergencies, while our Disaster Averted looks at a simple mistake that can have serious consequences. For this week’s Mastery In Minutes video presentation for you, we have Patricia Kringas, RN, CDE, who talks about some of the results of the TODAY study on type 2 adolescents.

NEWSFLASH: Takeda announced that the FDA has approved Nesina (alogliptin), Oseni (alogliptin and Pioglitazone), and Kazano (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.